ArticleAesthetic plastic surgery2026
Pilot Study of Combined Tranexamic Acid Therapy in Breast Reduction - Intravenous and Local Infiltration.
Article in Aesthetic plastic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTranexamic acid (TXA) reduces perioperative blood loss in several surgical fields; however, its role in breast reduction surgery remains unclear. This study aimed to evaluate the effect of combined TXA therapy (intravenous and local infiltration) on postoperative outcomes of patients who underwent modified Liacyr Ribeiro breast reduction.
methodsWe conducted a controlled, non-randomized pilot study of patients who underwent bilateral reduction mammoplasty by the same surgeon. The intervention group received 1 g of intravenous TXA at anesthesia induction and local infiltration with a 1-mg/mL TXA vasoconstrictive solution containing epinephrine. The control group received local infiltration with an identical vasoconstrictive solution that did not contain TXA. Primary outcomes were total and daily drain output. Secondary outcomes included length of hospital stay, time to drain removal, and postoperative complications.
resultsFifty-seven patients were included (31 in the control group and 26 in the intervention group). TXA significantly reduced the total postoperative drain volume (p<0.001) by an estimated 79% and drain output at 24h (p<0.003). In the TXA group, 53.8 % of the patients had unquantifiable drainage versus 9.7% in the control group (p=0.002). No significant differences were observed in complications, including hemorrhagic events, infections, or wound healing; indeed, the incidence of complications was low in both groups.
conclusionsCombined TXA therapy significantly and clinically meaningfully reduced postoperative drain output. This reduction anticipates drain removal and may ultimately contribute to the broader adoption of drain-free breast reduction surgery. LEVEL OF EVIDENCE II: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine Ratings, please refer to Table of Contents or online Instructions to Authors www.springer.com/00266 .
Indexed as
Identifiers
42627493What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.